-
In this well-designed, randomized, placebo-controlled clinical trial of antioxidant supplements for Alzheimer's disease, there was no benefit, and some agents were associated with worse outcome.
-
An alternate-day steroid protocol appears to be just as efficacious as every-day steroids over the long term in a group of patients with undifferentiated polymyositis, with less serious long-term side effects.
-
Multimodal brain imaging demonstrates extensive frontostriatal dysfunction in mild cognitive impairment in early Parkinson's disease.
-
Side effects of finasteride; new ruling on pharmaceutical companies paying generic manufacturers; and FDA actions.
-
In this long-term, population-based patient series, the authors explore the natural course of drug-resistant epilepsy and explore whether remission can be predicted by clinical features.
-
-
Analysis of intracranial pressure complexity using a non-linear method of multiscale entropy shows that it correlates with outcome after traumatic brain injury.
-
Mesenchymal stem cells for the treatment of multiple system atrophy is a promising potential therapy, but requires further investigation regarding both safety and efficacy.
-
Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
Continuation of combination therapy with donepezil and memantine appears to have a long-term beneficial effect for patients with moderate-to-severe Alzheimer's disease.
